Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKT1 | P31749 | 7/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.50 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.49 |
| ▸ | HRH2 | P25021 | 2/20 | 0.48 |
| ▸ | HRH1 | P35367 | 2/20 | 0.48 |
| ▸ | DPP4 | P27487 | 4/20 | 0.48 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | AKT2 | P31751 | 1/20 | 0.45 |
| ▸ | AKT3 | Q9Y243 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4213022 | 1.00 | AKT1 (0.54) | AKT1HDAC8CHRM1HRH2HRH1 | |
| SCHEMBL10180336 | 1.00 | AKT1 (0.54) | AKT1HDAC8CHRM1HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL4205419 | 0.98 | AKT1 (0.53) | AKT1HDAC8CHRM1HRH2HRH1 | |
| SCHEMBL10305171 | 0.98 | AKT1 (0.53) | AKT1HDAC8CHRM1HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL4211151 | 0.98 | AKT1 (0.53) | AKT1HDAC8CHRM1HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL4205423 | 0.98 | AKT1 (0.53) | AKT1HDAC8CHRM1HRH2HRH1 | |
| SCHEMBL6268215 | 0.87 | AKT1 (0.51) | AKT1HDAC8CHRM1HRH2HRH1 | |
| SCHEMBL6657766 | 0.85 | AKT1 (0.59) | AKT1CHRM1HRH2HRH1AKT2 | |
| SCHEMBL6657763 | 0.85 | AKT1 (0.59) | AKT1CHRM1HRH2HRH1AKT2 | |
| Hydrochloric Acid SCHEMBL3960080 | 0.84 | AKT1 (0.58) | AKT1HDAC8CHRM1HRH2HRH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303021-B2 | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds | ALLERGAN, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303021-B2 | Methods for treating cognitive disorders using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds | ALLERGAN, INC. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-1841743-B1 | 3-Aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN INC (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2474534-B1 | 3-Aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity | ALLERGAN INC (US) | 2015-07-29 | — | — | EP | disclosed |
| US-8927589-B2 | 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-aminopropionic acid amides and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-8927589-B2 | 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-aminopropionic acid amides and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| US-20140296287-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140296287-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140179925-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-20140179925-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8288556-B2 | 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity | ALLERGAN, INC. (US) | 2012-10-16 | — | — | US | disclosed |
| EP-2474534-A1 | 3-Aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immunostimulant activity | Allergan, Inc. (US) | 2012-07-11 | — | — | EP | disclosed |
| US-20100093793-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20100093793-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2010-04-15 | — | — | US | disclosed |
| US-20090036436-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | ALLERGAN, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036436-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | ALLERGAN, INC. | 2009-02-05 | — | — | US | disclosed |
| US-20090036436-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | ALLERGAN, INC. | 2009-02-05 | — | — | US | disclosed |
| WO-2008011478-A2 | METHODS FOR TREATING CHRONIC PAIN USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1841743-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | Allergan, Inc. (US) | 2007-10-10 | — | — | EP | disclosed |
| WO-2006081273-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROAYRYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITY | ALLERGAN, INC. (US) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036436-A1 | 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY | OPRL1, HCAR2, OPRM1 | AKT1 4670/4885HDAC8 1446/4885CHRM1 229/4885 |
| US-20140179925-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | SLC1A2, GRIN2C, GRIN2A | AKT1 4218/4885HDAC8 1816/4885CHRM1 624/4885 |
| US-20140296287-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | SLC1A2, GRIN2C, GRIN2A | AKT1 4218/4885HDAC8 1816/4885CHRM1 624/4885 |
| US-20100093793-A1 | METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | SLC1A2, AADAT, AANAT | AKT1 4222/4885HDAC8 1911/4885CHRM1 694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.